Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 368 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thromboembolism Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 21, 2026, 1:26 PM EDT
Completed No phase listed Observational Results available

Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures

NCT02037607
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
1 Month to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

NCT00709904
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Jul 21, 2026, 1:26 PM EDT
Recruiting Phase 2 Interventional

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

NCT04295486
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Aspirin
Drug
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
5,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 21, 2026, 1:26 PM EDT
Completed No phase listed Observational

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

NCT02461602
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Pasadena, California • Coral Springs, Florida • Port Charlotte, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jul 21, 2026, 1:26 PM EDT
Completed No phase listed Observational Results available

FlowTriever for Acute Massive Pulmonary Embolism (FLAME)

NCT04795167
View directory record Official record
Conditions
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
Interventions
Not listed
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Atlanta, Georgia • Royal Oak, Michigan • Southfield, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anticoagulation Medical Home

NCT02870296
View directory record Official record
Conditions
Venous Thromboembolism, Patient-Centered Care
Interventions
Enhanced Assessment and Education
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Jul 21, 2026, 1:26 PM EDT
Completed No phase listed Observational

Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data

NCT04736719
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
19,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

NCT00641732
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
TAK-442, Enoxaparin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Jul 21, 2026, 1:26 PM EDT
Completed No phase listed Observational

Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients

NCT00810784
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Education
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Phase 3 Interventional Results available

PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

NCT01274637
View directory record Official record
Conditions
Venous Thromboembolism, Postpartum
Interventions
Dalteparin Sodium
Drug
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Charlottesville, Virginia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 21, 2026, 1:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk Factors for Venous Thromboembolism

NCT00018772
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Phase 3 Interventional Results available

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

NCT01094886
View directory record Official record
Conditions
Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
Interventions
Rivaroxaban
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Denver, Colorado • Hollywood, Florida • Tamarac, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Phase 4 Interventional

EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization

NCT00077753
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
enoxaparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
4,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jul 21, 2026, 1:26 PM EDT
Terminated Phase 3 Interventional

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

NCT00580216
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
162
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Phase 1 Interventional

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

NCT00476216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Venous Thromboembolism
Interventions
Combination of Arixtra with chemotherapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Phase 4 Interventional

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

NCT02810704
View directory record Official record
Conditions
Pulmonary Embolism, Venous Thrombosis
Interventions
Enteric Coated Aspirin, Warfarin, Rivaroxaban
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
18,883 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 1:26 PM EDT
Completed No phase listed Observational

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

NCT02921828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 21, 2026, 1:26 PM EDT
Completed No phase listed Observational

Heparin or Enoxaparin in Patients With Cancer

NCT00004875
View directory record Official record
Conditions
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
enoxaparin, heparin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Jul 21, 2026, 1:26 PM EDT
Terminated No phase listed Observational Results available

Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)

NCT00594685
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
6 Months and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
21
States / cities
Atlanta, Georgia • Iowa City, Iowa • New Orleans, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Not applicable Interventional Results available

Once Weekly Subcutaneous Ports for the Administration of Anticoagulants

NCT00774748
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Insuflon
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Phase 4 Interventional Results available

Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty

NCT01809054
View directory record Official record
Conditions
Primary Total Hip and Knee Arthroplasty
Interventions
Arixtra, Pneumatic compression stockings, Aspirin
Drug · Device
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 21, 2026, 1:26 PM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Jul 21, 2026, 1:26 PM EDT